Industry News
Pharmaceutical Industry News
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is remarkable for a paralyzing, usually fatal disease.
The FDA’s Commissioner’s National…
The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.
In a bid to better deploy its…
In a bid to better deploy its boots-on-the-ground resources, the FDA is rolling out a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to complement its traditional site visits.
After several consecutive quarters…
After several consecutive quarters on the backfoot, Danish drug juggernaut Novo Nordisk is receiving warmer feedback on its starting performance in 2026, thanks in no small part to its head start over rival Eli Lilly
The FDA-conducted studies…
The FDA-conducted studies reportedly found COVID vaccines and GSK's shingles vaccine Shringrix safe and effective, according to The New York Times.
Cell and gene therapy developers…
Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report by Bayer’s venture capital wing.
Following a series of “most…
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administration released a report Tuesday projecting potential $529 billion in savings from the policy over the next 10 years.
Last month, when Optimi…
Last month, when Optimi Health kicked off an initial public offering of 2.5 million shares, the timing couldn’t have been better for the Vancouver-based manufacturer of psychedelic drugs. With President Donald Trump recently signing an executive order
With commitments to invest more…
With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an additional $4.5 billion to upgrade two of its three planned production facilities in Lebanon, Indiana.
As the promotion battle between…
As the promotion battle between old rivals Novo Nordisk and Eli Lilly heats up, regulators in France are reminding the world’s two biggest obesity drugmakers what happens when promotion goes too far.
CMI Media Group’s Jose Ferreira…
CMI Media Group’s Jose Ferreira on AI, omnichannel orchestration and delivering value in the moment for HCPs and consumers.
AI-driven search, zero-click…
AI-driven search, zero-click behavior and why context now defines pharma marketing success.
Why proactive evidence generation…
Why proactive evidence generation and coordination are critical for medical affairs teams to stand out.
With a better-than-expected first…
With a better-than-expected first quarter in the books, Pfizer—continuing to grapple with the post-pandemic overhang from its COVID-19 franchise—is sticking with the sales forecast it set earlier this year, raising questions from at least one
Novartis is continuing its…
Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany, by 2028. The move, announced Tuesday, will eliminate about 220 jobs, according to Novartis.
The German vaccine maker plans to…
The German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore, putting as many as 1,860 jobs on the chopping block.
Fresh off gaining an FDA expansion…
Fresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion.
Why consent, timing and…
Why consent, timing and closed-loop measurement are redefining how pharma brands engage HCPs.
Sanofi is supercharging its…
Sanofi is supercharging its artificial intelligence capabilities. The French pharma is investing $294 million to expand its global AI center of excellence in Toronto, kicking off a scale-up of the digital infrastructure it built at
Neurocrine Biosciences has shared…
Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.